Announcements Trials

Browse Landscape

Phase

Phase 2 24 Phase 3 6 Phase 1 5 Phase EARLY_PHASE1 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 13 gallium 68 PSMA-11 8 Fluorodeoxyglucose F18 5 Specimen Handling 4 Positron Emission Tomography Computed Tomography 4 2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 4 enzalutamide 3 Nivolumab 3 Ipilimumab 3 Interleukin-2 3 Biopsy 3 68Ga-DKFZ-PSMA-11 3 pembrolizumab 2 pazopanib 2 lenvatinib 2 bicalutamide 2 atezolizumab 2 aldesleukin 2 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 2 X-Rays 2 Standard of Care 2 Radiation 2 Positron-Emission Tomography 2 Paclitaxel 2 Oncolytic Virotherapy 2 Nephrectomy 2 Metformin 2 Metastasectomy 2 Immunoglobulin G 2 Hydroxychloroquine 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase EARLY_PHASE1 × relugolix × Genitourinary × Clear all

NCT07069465 2025-07-16

PIONEER PSMA

Urology Clinics of North Texas

Phase EARLY_PHASE1 Completed

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡